Financing channel feed – Endpoints News

Financing channel feed

Arsanis prices $40M IPO for infectious disease work

8 years ago

X4 raises $27M to take Sanofi’s old drug through pivotal trial

8 years ago

Johns Hopkins has $65M to spend on taking their drugs right up to human studies

8 years ago

$49M round; experienced team; A-list VCs — Inozyme launches with rare disease strategy and a yen for bigger things to come

8 years ago

Award-winning sepsis project gets $13M and a shot at reopening an R&D avenue as FDA pitches out old gold standard

8 years ago

San Diego’s stealthy Odonate surfaces with $173M IPO

8 years ago

ImmusanT scores a $40M round for PhII celiac study, with biotech vet Tom Daniel joining the board

8 years ago

Torque takes tumor tech out of stealth with $25M backing, new CEO

8 years ago

Neurodegeneration upstart Denali outlines $100M IPO for its growing clinical work

8 years ago

Google backs I/O startup Arcus in $107M deal

8 years ago

Bill Gates has a $100M and a 5-point strategy to end 15 years of failure in Alzheimer’s R&D

8 years ago

Hunting for early-stage life sciences bets, Partners Healthcare closes $171M for venture fund

8 years ago

Prepping PhIII for Soliris rival, Apellis rides a boisterous market to a $150M IPO

8 years ago

Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics

8 years ago

German biotech InflaRx raises $100M in IPO

8 years ago

Amgen bets on stem cell company Fortuna Fix in $25M round

8 years ago

Upstart Oyster Point has big plans for disrupting the ophthalmology space, but you'll have to wait for the details

8 years ago

Boasting in-license distribution model, Chinese EOC Pharma bags $32M series B funding for oncology products

8 years ago

Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure

8 years ago

Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

8 years ago

IPO market warms with Spero, Allena heading to Wall Street

8 years ago

Shkreli out, Cuban in: Twitter proves essential for biotech rebel Ethan Perlstein

8 years ago

Frazier boosts next pure-play biotech fund to $419M, readies new bets for a practiced strategy

8 years ago

Bristol-Myers, J&J sink cash into a new $95M European biotech fund

8 years ago

First page Previous page 134 135 136137138 139 140 Next page Last page